Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174199 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01174199 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 13 participants.
The verdict
NCT01174199, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus and vorinostat in treating patients with metastatic prostate cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG vorinostat
- DRUG temsirolimus
- PROCEDURE positron emission tomography/computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174199
The ClinicalTrials.gov registry entry for NCT01174199 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01174199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174199 about?
NCT01174199 is a clinical study titled "Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Temsirolimus and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with vorinostat may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of temsirolimus and vorinos...
What is the current status of trial NCT01174199?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-02. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01174199?
The interventions under investigation include: laboratory biomarker analysis (OTHER), vorinostat (DRUG), temsirolimus (DRUG), positron emission tomography/computed tomography (PROCEDURE).
Who is sponsoring clinical trial NCT01174199?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.